IWWM-11 2022 | Treatment and survival outcomes in patients with WM complicated by AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses a study which evaluated the clinical characteristics, treatment, and survival outcomes of patients with Waldenström’s macroglobulinemia (WM)-associated light chain (AL) amyloidosis. Dr Sanchorawala first highlights the diagnosis, organ involvement, and genomic mutations observed, and then goes on to discuss the efficacy of various treatment approaches, including rituximab-bendamustine, bortezomib plus dexamethasone and rituximab (BDR), and melphalan and autologous stem cell transplantation. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Membership on an entity’s Board of Directors or advisory committees; Proclara: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.
